深度RNA测序揭示融合连接异质性可预测克唑替尼治疗ALK重排NSCLC的疗效
研究纳入51例接受克唑替尼治疗的ALK重排NSCLC患者,用靶向RNA测序分析治疗前肿瘤组织。47.1%肿瘤存在多种EML4-ALK RNA异构体,多异构体患者调整混杂因素后无进展生存(HR 2.45,95%CI 1.06-5.69)和总生存(HR 3.74,95%CI 1.26-11.13)均更差,提示瘤内融合异构体异质性可能预测靶向治疗疗效。
要点
- 多EML4-ALK RNA异构体患者克唑替尼治疗后PFS和OS显著更差
- v3肿瘤多同时携带v3a和v3b两种RNA异构体
- 单细胞PCR显示H2228细胞多数仅表达v3a或v3b之一
核心结论
- 瘤内EML4-ALK RNA异构体异质性可能预测ALK重排NSCLC靶向治疗疗效,多异构体提示预后更差。
研究设计与样本
- 回顾性队列研究,纳入51例接受克唑替尼治疗的ALK重排NSCLC患者,治疗前肿瘤组织行锚定多重PCR靶向RNA测序。
- 采用Kaplan-Meier和Cox回归比较总生存和无进展生存。
主要发现
- EML4-ALK变异类型v1、v2、v3和其他分别检出23例(45.1%)、5例(9.8%)、19例(37.3%)和4例(7.8%)。
- 24个肿瘤(47.1%)检出多种EML4-ALK RNA异构体,27个(52.9%)为单一异构体。
- 19例v3肿瘤中16例同时携带v3a和v3b RNA异构体;8例非v3肿瘤(占24例多异构体的33.3%;5例v1、2例v5'、1例v2)也检出多异构体。
- 调整包括变异类型在内的潜在混杂因素后,多异构体患者较单一异构体患者无进展生存更差(HR 2.45,95%CI 1.06-5.69),总生存也更差(HR 3.74,95%CI 1.26-11.13)。
- H2228细胞单细胞PCR显示多数单细胞仅检出v3a或v3b之一;三种ALK抑制剂处理后v3a与v3b表达比值随时间增加。
临床怎么用
- 对ALK重排NSCLC患者,治疗前RNA测序检测EML4-ALK异构体多样性可能有助于识别克唑替尼疗效较差的高危人群。
局限性
- 样本量较小(51例),结论需更大规模RNA测序研究验证。
- 异构体随时间变化及药物选择压力的机制主要基于H2228细胞系实验,临床相关性待证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Gene fusion variants in ALK-rearranged NSCLC may predict patient outcomes, but previous results have been inconclusive. Fusion isoforms coexisting in the same tumor may affect the efficacy of targeted therapy, but they have not been investigated. METHODS: Patients with ALK-rearranged NSCLC who received crizotinib treatments were recruited. Precrizotinib tumor tissues were analyzed by the anchored multiplex polymerase chain reaction for targeted RNA sequencing. Kaplan-Meier and Cox regression were used to compare overall and progression-free survivals. RESULTS: Of the 51 studied subjects, EML4-ALK variant types v1, v2, v3, and others were detected in 23 (45.1%), five (9.8%), 19 (37.3%), and four patients (7.8%), respectively. Multiple EML4-ALK RNA isoforms were detected in 24 tumors (47.1%), and single isoform in 27 (52.9%). Most of the v3 tumors (16 of 19) harbored both v3a and v3b RNA isoforms. Multiple isoforms were also detected in eight non-v3 tumors (33.3% of all 24 multiple isoforms; five v1, two v5', and one v2). Compared with patients with single isoform, those with multiple isoforms had worse progression-free (hazard ratio and 95% confidence interval: 2.45 [1.06-5.69]) and overall (hazard ratio [95% confidence interval]: 3.74 [1.26-11.13]) survivals after adjusting for potential confounders including variant type. Using the patient-derived H2228 cells known to express v3a and v3b, our single-cell polymerase chain reaction detected either v3a or v3b in most single cells. Treatment of H2228 cells by three ALK inhibitors revealed increased ratios of v3a-to-v3b expression over time. CONCLUSIONS: Intratumoral EML4-ALK isoforms may predict the efficacy of targeted therapy in ALK-rearranged NSCLC. Temporal changes of intratumoral fusion isoforms may result from differential selection pressures that a drug might have on one isoform over another. Larger studies on fusion heterogeneity using RNA sequencing are warranted.
引用
- Song Z, Lian S, Mak S, et al. Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLC. J Thorac Oncol. 2021. PMID: 34626839. doi:10.1016/j.jtho.2021.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。